December 5-7th, 2017

Miami, FL

REGISTER NOW AND SAVE UP TO $600

Speakers

Expand/Collapse

Matt Mulvey
CEO
Benevir Biopharm

Mulvey is a founder and CEO of BeneVir and an inventor on all BeneVir patents protecting T-StealthTM Technology, an oncolytic virus platform that resists both innate and adaptive anti-viral immunity. Prior to BeneVir, Mulvey spent 8 years at Sequella, Inc., a clinical stage anti-infectives company. Mulvey holds a PhD in Virology from Ian Mohr’s lab at NYU Langone Medical Center. Mohr and Mulvey discovered, patented, and characterized the first oncolytic virus capable of resisting the anti-viral effects of innate immunity. This intellectual property was licensed to create talimogene laherparepvec (T-Vec), which became the first FDA approved oncolytic virus.

Day One

Tuesday December 5th, 2017

12.30 | T-StealthTM Technology Promotes Synergy Between Oncolytic Viruses and Immuno-Stimulatory Agents

Matteo Di Piazza
Principal Scientist
Boehringer Ingelheim

Day One

Tuesday December 5th, 2017

14.30 | Roundtable Discussion: Preclinical Drug Safety

Frank Tufaro
CEO
DNAtrix

Frank Tufaro, Ph.D. started his career as a virologist and professor at the University of British Columbia (Vancouver, Canada), where he studied herpesviruses as well as proteoglycan biosynthesis. From there, Frank founded NeuroVir, a biotech company developing oncolytic herpesvirus therapy for cancer. Dr. Tufaro jointed DNAtrix in 2007, a company developing adenovirus Delta-24-RGD for brain tumors and other cancers.  As DNAtrix CEO, Dr. Tufaro has raised over $30 million in private funding and has been awarded over $14 million in research grants.  Frank has lived in San Diego for the past 15 years, and serves on the board of several public and private biotech companies.

Samuel Rabkin
Professor of Neurosciences, Neurosurgery
Harvard Medical School

Samuel D. Rabkin is the Thomas A. Pappas Professor in Neurosciences and Professor of Neurosurgery (Microbiology & Immunobiology) at Harvard Medical School, Boston MA, and Virologist in Neurosurgery at Massachusetts General Hospital, Boston, MA.  He is an Associate Editor of Molecular Therapy-Oncolytics.  After obtaining his PhD at the University of Chicago, he was an Assistant Member in Molecular Biology at Memorial Sloan-Kettering Cancer Center, New York, NY, and an Associate Professor in Neurosurgery at Georgetown University Medical Center, Washington DC.  Dr. Rabkin's research has focused on the development of oncolytic herpes simplex viruses for cancer therapy.  He is an inventor on 14 US patents.

Workshop A

Thursday December 7th

09.00 |

Novel Approaches for Oncolytic Virus Combination Therapies

Robert Andtbacka
Co-Director Melanoma Program & Melanoma Clinical Research Program
Huntsman Cancer Institute

Dr. Andtbacka is board certified in general surgery by the American Board of Surgery and the Royal College of Surgeons of Canada. He is the Utah State Chair for the Commission on Cancer, and is a guideline committee member on the Melanoma Committee for the National Comprehensive Cancer Network. He specializes in surgery for melanoma, skin cancer, soft tissue sarcomas, and cancers of the gastrointestinal tract. He is a leader in using novel injectable intratumoral agents in melanoma and he is the principal investigator for several clinical trials designed to improve diagnosis and treatments for cancer patients.

Day One

Tuesday December 5th, 2017

09.30 | Development Strategy of HF10, a Spontaneous Mutant Herpes Simplex Virus

Angelica Loskog
CEO
Lokon Pharma

Angelica Loskog is the CEO of the Swedish biotech company Lokon Pharma AB that develops oncolytic virus therapy for cancer. She is also adjunct as a full professor of immunotherapy to Uppsala University where she leads a translational research group running clinical Phase I/II trials with virus therapeutics and CAR T cells.

Day Two

Wednesday December 6th, 2017

09.30 | Local LOAd703 Virus Administration Results in Enhanced Efficacy Compared to Systemic Treatment.

Matt Coffey
CEO
Oncolytics Biotech

Day Two

Wednesday December 6th, 2017

13.00 | Immune and Genetic Markers in Randomized Clinical Studies using REOLYSIN®

Charles Morris
CDO
PsiOxus Therapeutics

Dr Charles Morris is a Medical Oncologist with over 20 years of cancer drug development experience in the pharmaceutical and biotechnology industries. Having gained clinical and research experience at The Christie Hospital in Manchester, UK, he joined Zeneca (later AstraZeneca) Pharmaceuticals where he was involved in the development of a number of oncology agents including fulvestrant and gefitinib. Having gained experience across all phases of drug development, he later joined Cephalon where he was Vice President Clinical Research, Oncology, helping to secure approvals for bendamustine in two hematology-oncology indications. He later became Chief Medical Officer at Allos Therapeutics – which was acquired by Spectrum Pharmaceuticals in 2012 – and then Chief Development Officer at ImmunoGen, Inc., leading the development of their proprietary pipeline of antibody drug conjugates. Dr Morris is a graduate of Sheffield University Medical School and is a Member of the Royal College of Physicians.

Day One

Tuesday December 5th, 2017

11.30 | An Oncolytic Virus Expressing a FAP-Specific T-Cell Engager to Target Stroma-Rich Tumors

Day Two

Wednesday December 6th, 2017

11.00 | PANEL: How Can We Improve The Efficacy of Oncolytic Virotherapies?

Rob Coffin
CEO
Replimune

Dr. Robert Coffin MD Co-Founded BioVex Group, Inc., and served as its Chief Scientific Officer since 1999. Mr. Astley-Sparke served as Chief Technology Officer of BioVex, Inc. Dr. Coffin was a founding scientist and Lecturer in Virology and Gene Therapy at University College London and Honorary Senior Lecturer at The Institute of Child Health. He is an expert in the application of virus-based technology to the development of therapeutic products and vaccines, has authored more than 50 scientific papers and is a named inventor on all of the patents filed in BioVex name. He served as Director of BioVex Group, Inc. Dr. Coffin received his PhD in 1991 from Imperial College, London, following which he moved to University College London where he ultimately led the research group.

Day One

Tuesday December 5th, 2017

14.00 | Introducing Replimune’s Next Generation “Immulytic™” Oncolytic Immunotherapy Platform

Day Two

Wednesday December 6th, 2017

11.00 | PANEL: How Can We Improve The Efficacy of Oncolytic Virotherapies?

Douglas Jolly
EVP, Research & Pharmaceutical Development
Tocagen

Douglas Jolly, Ph.D., is a co-founder of Tocagen and has served as our executive vice president, research and pharmaceutical development since December 2007. He is an internationally recognized expert in the field of gene therapy and its pharmaceutical application. Over the last 25 years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., where he was also a co-founder, Chiron Corporation, Oxford BioMedica plc, where he ran the U.S. subsidiary, BioMedica Inc., and Advantagene, Inc., where he most recently served as president. He has published more than one hundred scientific articles and is an inventor on more than forty-five issued patents. Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute; Harvard Medical School; Scripps Clinic; University of California, San Diego; and The French National Institute for Health and Medical Research, INSERM, in Paris. Dr. Jolly holds a doctorate in biochemistry from the University of Glasgow. Dr. Jolly is a board member, chairman of the Industrial Liaison Committee, and also currently serves as a member of the Translational Medicine Committee of the American Society of Gene & Cell Therapy.

Day Two

Wednesday December 6th, 2017

14.30 | Understanding the Risks of Viral Shedding and Ensuring Steps are in Place to Deal with Potential Negative Effects

Monika Lusky
Director
Transgene

Monika Lusky, PhD, has more than 30 years’ experience in studying, optimizing and developing viral-based therapies. As a Director and Senior program leader at Transgene, she coordinates the clinical development of two clinical stage immunotherapies: Pexa-Vec and TG4001, with a particular focus on combinations with immune checkpoint inhibitors. Previously, Monika was Senior Scientific Analyst and Head of the adenovirology laboratory at Transgene, where she acquired an extensive and in-depth knowledge of viral-based therapies. She was an Associate Professor within the Department of Microbiology at Cornell University Medical College (NY, USA). Monika Lusky has a PhD in Molecular Biology and Genetics. She authored more than 50 articles published in international scientific journals.

Day Two

Wednesday December 6th, 2017

12.00 | Vaccinia Virus-based Oncolytic Immunotherapy: Ongoing Early and Late Stage Clinical Development

Noriyuki Kasahara
Professor, Departments of Cell Biology and Pathology
University of Miami

Early in Dr. Kasahara's career, he was involved in research showing that thymidylate synthase (TS) and thymidine kinase (TK) are highly upregulated to support rapid DNA replication and cell proliferation during carcinogenesis, and can serve both as diagnostic biomarkers as well as chemotherapeutic targets. Dr. Kasahara's current research focuses on the application of genetic engineering and gene therapy technologies to the fields of cancer, transplantation, and regenerative medicine. Dr. Kashara and his lab have pursued translationally-relevant strategies, including (1) development of novel hybrid virus vectors, cancer-targeted vectors, and tumor-selectively replicating virus vectors, (2) development of genetically-engineered cancer cell vaccines and dendritic cell vaccines, as well as adoptive immunotherapy with cancer-targeted alloreactive T cells, and (3) development of methods for genetic modification of histocompatibility and in vivo chemoselection of hematopoietic stem cells.

Day Two

Wednesday December 6th, 2017

15.00 | Ensuring Healthcare Facilities are Primed for “live” Oncolytic Virotherapies

Sari Pesonen
VP, Scientific & Clinical Development
Valo Therapeutics

Sari Pesonen, VP Scientific and Clinical Development (PhD, co-founder) at Valo Therapeutics. Previously she worked at Oncos Therapeutics as a Research Director and later took on the role of Head of Clinical Science, leading clinical sample analysis. Later, Sari worked as VP Preclinical Research and Clinical Science at Targovax. Sari gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki in a research group focusing on the development of oncolytic viruses for the treatment of cancer. She is a co-author on 60+ peer-reviewed research papers.

Day One

Tuesday December 5th, 2017

12.00 | PeptiCRAd™: An Innovative Oncolytic Vaccine Platform to Refocus the Immune Response from Virus to Tumor

Stephen Russell
CEO
Vyriad

Stephen J. Russell is currently the Richard O. Jacobson Professor of Molecular Medicine at Mayo Clinic in Rochester, Minnesota.  He obtained his M.B.Ch.B. from the University of Edinburgh, PhD. from University of London, and received specialist accreditation in Medicine and Haematology.  In 1998, he took the position of Director of the Molecular Medicine Program Mayo Clinic in Rochester, Minnesota and subsequently became Department Chair when the Program was converted to a department.   His research is focused on developing engineered viruses for the treatment of disseminated malignancies (particularly multiple myeloma) and demonstrating their efficacy in clinical trials.  Research themes in his laboratory include the engineering of viral membrane glycoproteins, targeting cell to cell fusion, targeting virus entry, using cellular microRNAs to reprogramme virus tropism, pharmacokinetic and pharmacodynamic studies of virus-based therapies, noninvasive monitoring and imaging of viral gene expression in vivo, and radiovirotherapy.  He is a practicing haematologist.

Workshop B

Thursday December 7th

13.00 |

Optimizing Oncolytic Viruses: Identifying the Right Viral Platform

Day Two

Wednesday December 6th, 2017

12.30 | VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms.

11.00 | PANEL: How Can We Improve The Efficacy of Oncolytic Virotherapies?

Stephen Thorne
CEO
Western Oncolytics

Stephen Thorne trained at Oxford University and Imperial College, London with additional post-doctoral experience at Cancer Research UK and Stanford University. He also helped found Jennerex biotherapeutics. While working as an Assistant Professor at the University of Pittsburgh his lab developed the technology that has been licensed by Western Oncolytics. He is currently CSO at Western Oncolytics.

Day Two

Wednesday December 6th, 2017

10.00 | Achieving the Right Viral Volumes and Dosages Effectively